Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Axogen's peak revenue was $187.3M in 2024. The peak quarterly revenue was $49.4M in 2024(q4).
Axogen's revenue increased from $3.0m in 2010 to $187.3M currently. That's a 6,135.36% change in annual revenue.
| Fiscal year / year | Axogen revenue |
|---|---|
| 2010 | $3.0M |
| 2011 | $4.8M |
| 2012 | $7.7M |
| 2013 | $10.9M |
| 2014 | $16.8M |
| 2015 | $27.3M |
| 2016 | $41.1M |
| 2017 | $60.4M |
| 2018 | $83.9M |
| 2019 | $106.7M |
| 2020 | $112.3M |
| 2021 | $127.4M |
| 2022 | $138.6M |
| 2023 | $159.0M |
| 2024 | $187.3M |
How accurately did Axogen's revenue projections match actual performance?
Axogen saw the greatest revenue growth in 2015, when revenue increased by 62.52%.
Axogen had the lowest revenue growth in 2020, when revenue changed by 5.24%.
| Year | Axogen growth |
|---|---|
| 2011 | 61%↑ |
| 2012 | 59%↑ |
| 2013 | 42%↑ |
| 2014 | 54%↑ |
| 2015 | 63%↑ |
| 2016 | 50%↑ |
| 2017 | 47%↑ |
| 2018 | 39%↑ |
| 2019 | 27%↑ |
| 2020 | 5%↑ |
| 2021 | 13%↑ |
| 2022 | 9%↑ |
| 2023 | 15%↑ |
| 2024 | 18%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | $1.2M | $1.1M | $1.4M |
| 2012 | $1.7M | $2.0M | $2.0M | $2.0M |
| 2013 | $2.1M | $2.9M | $3.0M | $3.0M |
| 2014 | $3.1M | $4.2M | $4.7M | $4.8M |
| 2015 | $5.0M | $6.4M | $8.2M | $7.8M |
| 2016 | $8.1M | $10.4M | $11.2M | $11.4M |
| 2017 | $12.2M | $15.2M | $16.0M | $17.0M |
| 2018 | $17.3M | $20.6M | $22.7M | $23.4M |
| 2019 | $23.3M | $26.7M | $28.6M | $28.2M |
| 2020 | $24.3M | $22.1M | $33.4M | $32.5M |
| 2021 | $31.0M | $33.6M | $31.2M | $31.5M |
| 2022 | $31.0M | $34.5M | $37.0M | $36.2M |
| 2023 | $36.7M | $38.2M | $41.3M | $42.9M |
| 2024 | $41.4M | $47.9M | $48.6M | $49.4M |
Do you work at Axogen?
Is Axogen transparent about its revenue structure?
| CEO | Ms. Karen L. Zaderej |
| Company Type | Public |
| Employees Number | 297 |
| Date Founded | 2002 |
| Headquarters | Alachua, Florida |
| Number of Locations | 5 |
| Revenue | $187.3M |
| Net Income | -$28,948,000 |
| Gross Proft | $142.0M (2024) |
| PE Ratio | -129.95 |
| Tax Rate | 0.1% |
| Market Capitalization | $1.3B |
| Total Assets | $195,387,000 |
| Ticker | AXGN |
Axogen received early financing of $12.1M on 2007-12-17.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $12.1M | 12/2007 |
| Debt Financing | $2.6M | 06/2009 |
| Debt Financing | $3.7M | 01/2011 |
| Debt Financing | $3M | 06/2011 |
| Post Ipo Equity | $18M | 08/2013 |
| Post Ipo Equity | $13M | 02/2015 |
| Post Ipo Equity | $17.5M | 08/2015 |
| Investors | Security type |
|---|---|
| Cardinal Partners | Post Ipo Equity |
| DE NOVO VENTURES | Post Ipo Equity |
| Springboard Capital | Post Ipo Equity |
| Accuitive Medical Ventures | Post Ipo Equity |
| Essex Woodlands Health Ventures | Post Ipo Equity |
Axogen's top competitor, Zoetis, earned an annual revenue of $9.3B.
Axogen's smallest competitor is Invivoscribe with revenue of $6.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Ethicon | $62,256 | $4.9B | 11,000 | - |
| CoolSculpting | $73,648 | $342.1M | 686 | - |
| Molecular Devices | $85,783 | $150.0M | 631 | - |
| Zoetis | $87,092 | $9.3B | 11,300 | 308 |
| Cytori Therapeutics | $50,366 | $7.4M | 12 | - |
| RTI Surgical | $64,097 | $280.0M | 942 | 26 |
| Branch Medical Group | $42,923 | $580,000 | 9 | - |
| Fresenius Kabi | $44,731 | $800.0M | 72 | 102 |
| Immucor | $60,486 | $380.0M | 1,125 | - |
| CIMA Labs | $74,201 | $8.5M | 120 | 33 |
Zippia gives an in-depth look into the details of Axogen, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Axogen. The employee data is based on information from people who have self-reported their past or current employments at Axogen. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Axogen. The data presented on this page does not represent the view of Axogen and its employees or that of Zippia.
Axogen may also be known as or be related to AXOGEN INC., AxoGen, AxoGen Inc, AxoGen, Inc., Axogen, Axogen Corporation and Axogen, Inc.